DFDA

Donepezil

Treatment for Vascular Dementia

Typical Dosage: 5-10 mg daily

Effectiveness
65%
Safety Score
60%
Clinical Trials
9
Participants
15K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
5-10 mg daily
Time to Effect
1-3 months
Treatment Duration
Lifetime
Evidence Quality
MODERATE
Number Needed to Treat (NNT)
15(Treat 15 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
25(Treat 25 patients to see 1 additional serious adverse event)
Confidence Score
70%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$100
Monitoring:$500
Side Effect Mgmt:$100
Total Annual:$700
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
0.08
Outcome-Based Costs
Cost per Responder
$2,000
Donepezil Outcomes

for Vascular Dementia

Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+35%
Common Side Effects
Nausea
+15%
Diarrhea
+10%
Insomnia
+10%
Vomiting
+5%

Sources:

scite.ai
medscape.com
karger.com

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov

Completed Clinical Trials
6 completed trials for Donepezil in Vascular Dementia

Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia

NCT00165763COMPLETEDPHASE4
View Study
36 participants
INTERVENTIONAL
Quezon, Philippines +1 more
Started: Sep 1, 2005

Donepezil Hydrochloride (E2020) in Dementia Associated With Cerebrovascular Disease

NCT00165737COMPLETEDPHASE3
View Study
974 participants
INTERVENTIONAL
Hot Springs, United States +4 more
Started: Mar 1, 2003

Non-Interventional Study With Aricept® Evess

NCT00889603COMPLETED
View Study
370 participants
OBSERVATIONAL
Bacau, Romania +11 more
Started: May 1, 2009

Efficacy and Safety of Tianzhi Granule in Mild to Moderate Vascular Dementia

NCT02453932COMPLETEDPHASE3
View Study
543 participants
INTERVENTIONAL
Beijing, China
Started: Oct 1, 2013

Safety of Donepezil in Patients With Dementia Associated With Cerebrovascular Disease

NCT00188812COMPLETEDPHASE3
View Study
INTERVENTIONAL
Toronto, Canada
Started: May 1, 2004

Masitinib in Patients With Mild to Moderate Alzheimer's Disease

NCT01872598COMPLETEDPHASE3
View Study
721 participants
INTERVENTIONAL
Varna, Bulgaria +5 more
Started: Jan 1, 2012